Hippocampal subfield volumes and pre-clinical Alzheimer's disease in 408 cognitively normal adults born in 1946.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 01 08 2019
accepted: 03 10 2019
entrez: 18 10 2019
pubmed: 18 10 2019
medline: 18 3 2020
Statut: epublish

Résumé

The human hippocampus comprises a number of interconnected histologically and functionally distinct subfields, which may be differentially influenced by cerebral pathology. Automated techniques are now available that estimate hippocampal subfield volumes using in vivo structural MRI data. To date, research investigating the influence of cerebral β-amyloid deposition-one of the earliest hypothesised changes in the pathophysiological continuum of Alzheimer's disease-on hippocampal subfield volumes in cognitively normal older individuals, has been limited. Using cross-sectional data from 408 cognitively normal individuals born in mainland Britain (age range at time of assessment = 69.2-71.9 years) who underwent cognitive assessment, 18F-Florbetapir PET and structural MRI on the same 3 Tesla PET/MR unit (spatial resolution 1.1 x 1.1 x 1.1. mm), we investigated the influences of β-amyloid status, age at scan, and global white matter hyperintensity volume on: CA1, CA2/3, CA4, dentate gyrus, presubiculum and subiculum volumes, adjusting for sex and total intracranial volume. Compared to β-amyloid negative participants (n = 334), β-amyloid positive participants (n = 74) had lower volume of the presubiculum (3.4% smaller, p = 0.012). Despite an age range at scanning of just 2.7 years, older age at time of scanning was associated with lower CA1 (p = 0.007), CA4 (p = 0.004), dentate gyrus (p = 0.002), and subiculum (p = 0.035) volumes. There was no evidence that white matter hyperintensity volume was associated with any subfield volumes. These data provide evidence of differential associations in cognitively normal older adults between hippocampal subfield volumes and β-amyloid deposition and, increasing age at time of scan. The relatively selective effect of lower presubiculum volume in the β-amyloid positive group potentially suggest that the presubiculum may be an area of early and relatively specific volume loss in the pathophysiological continuum of Alzheimer's disease. Future work using higher resolution imaging will be key to exploring these findings further.

Sections du résumé

BACKGROUND
The human hippocampus comprises a number of interconnected histologically and functionally distinct subfields, which may be differentially influenced by cerebral pathology. Automated techniques are now available that estimate hippocampal subfield volumes using in vivo structural MRI data. To date, research investigating the influence of cerebral β-amyloid deposition-one of the earliest hypothesised changes in the pathophysiological continuum of Alzheimer's disease-on hippocampal subfield volumes in cognitively normal older individuals, has been limited.
METHODS
Using cross-sectional data from 408 cognitively normal individuals born in mainland Britain (age range at time of assessment = 69.2-71.9 years) who underwent cognitive assessment, 18F-Florbetapir PET and structural MRI on the same 3 Tesla PET/MR unit (spatial resolution 1.1 x 1.1 x 1.1. mm), we investigated the influences of β-amyloid status, age at scan, and global white matter hyperintensity volume on: CA1, CA2/3, CA4, dentate gyrus, presubiculum and subiculum volumes, adjusting for sex and total intracranial volume.
RESULTS
Compared to β-amyloid negative participants (n = 334), β-amyloid positive participants (n = 74) had lower volume of the presubiculum (3.4% smaller, p = 0.012). Despite an age range at scanning of just 2.7 years, older age at time of scanning was associated with lower CA1 (p = 0.007), CA4 (p = 0.004), dentate gyrus (p = 0.002), and subiculum (p = 0.035) volumes. There was no evidence that white matter hyperintensity volume was associated with any subfield volumes.
CONCLUSION
These data provide evidence of differential associations in cognitively normal older adults between hippocampal subfield volumes and β-amyloid deposition and, increasing age at time of scan. The relatively selective effect of lower presubiculum volume in the β-amyloid positive group potentially suggest that the presubiculum may be an area of early and relatively specific volume loss in the pathophysiological continuum of Alzheimer's disease. Future work using higher resolution imaging will be key to exploring these findings further.

Identifiants

pubmed: 31622410
doi: 10.1371/journal.pone.0224030
pii: PONE-D-19-21691
pmc: PMC6797197
doi:

Substances chimiques

Amyloid 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0224030

Subventions

Organisme : Medical Research Council
ID : MC_UU_12019/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L023784/1
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Medical Research Council
ID : CSUB19166
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12019/2
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/17/90/33415
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L023784/2
Pays : United Kingdom
Organisme : EPA
ID : EP-W-17-011
Pays : United States
Organisme : Medical Research Council
ID : MC_UU_12019/3
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00019/3
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 200109/Z/15/Z
Pays : United Kingdom

Déclaration de conflit d'intérêts

NCF’s research group has received payment for consultancy or for conducting studies from Biogen, Eli Lilly Research Laboratories, GE Healthcare, and Roche. NCF receives no personal compensation for the activities mentioned above. JMS has received research funding from Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly), has consulted for Roche Pharmaceuticals, Biogen, Merck and Eli Lilly, given educational lectures sponsored by GE Healthcare, Eli Lilly and Biogen, and serves on a Data Safety Monitoring Committee for Axon Neuroscience SE. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Références

JAMA Neurol. 2013 Jul;70(7):903-11
pubmed: 23712469
Brain Res. 1989 Aug 7;494(1):198-203
pubmed: 2765920
J Neurol Neurosurg Psychiatry. 1992 Oct;55(10):967-72
pubmed: 1431963
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
J Nucl Med. 2013 Jan;54(1):70-7
pubmed: 23166389
Eur J Epidemiol. 2016 Nov;31(11):1135-1147
pubmed: 27995394
Front Aging Neurosci. 2014 Sep 25;6:261
pubmed: 25309437
Lancet Neurol. 2018 Apr;17(4):335-346
pubmed: 29500152
Nat Rev Neurosci. 2011 Sep 07;12(10):585-601
pubmed: 21897434
Arch Neurol. 2006 May;63(5):693-9
pubmed: 16682538
Int Psychogeriatr. 2017 Apr;29(4):545-555
pubmed: 28088928
Hippocampus. 2009 Jun;19(6):558-64
pubmed: 19405132
Hippocampus. 2017 Mar;27(3):249-262
pubmed: 27933676
J Alzheimers Dis. 2015;45(1):27-33
pubmed: 25428255
Neuroimage. 2006 Apr 1;30(2):436-43
pubmed: 16300968
BMC Res Notes. 2018 Dec 13;11(1):885
pubmed: 30545411
J Gerontol A Biol Sci Med Sci. 2006 Jul;61(7):694-701
pubmed: 16870631
Arch Neurol. 2011 Nov;68(11):1404-11
pubmed: 21747008
N Engl J Med. 2018 May 3;378(18):1691-1703
pubmed: 29719179
Magn Reson Med. 1988 Oct;8(2):200-8
pubmed: 3210957
BMC Neurol. 2017 Apr 18;17(1):75
pubmed: 28420323
Neuroimage. 2015 Jul 15;115:117-37
pubmed: 25936807
Neurology. 2010 Jan 12;74(2):121-7
pubmed: 20065247
Neuroscience. 2015 Nov 19;309:29-50
pubmed: 26306871
Neurology. 2000 Aug 22;55(4):484-89
pubmed: 10953178
Neurology. 2005 Aug 23;65(4):559-64
pubmed: 16116116
Eur J Ageing. 2013 Jun;10(2):145-157
pubmed: 23637643
Neuroscience. 2000;95(3):721-5
pubmed: 10670438
JAMA Neurol. 2016 Jan;73(1):85-92
pubmed: 26595683
Brain. 2009 May;132(Pt 5):1310-23
pubmed: 19042931
Clin Neuropsychol. 2014;28(5):771-85
pubmed: 24815535
Neurobiol Aging. 2017 Nov;59:121-134
pubmed: 28886957
Neuroimage Clin. 2013 Aug 14;3:155-62
pubmed: 24179859
Ageing Res Rev. 2016 Sep;30:25-48
pubmed: 26827786
Neuroimage. 2015 Jan 1;104:366-72
pubmed: 25255942
Hum Brain Mapp. 2018 Feb;39(2):971-984
pubmed: 29164798
Neurology. 1991 Jan;41(1):51-4
pubmed: 1985296
Eur J Nucl Med Mol Imaging. 2015 Aug;42(9):1447-58
pubmed: 26105119
J Nucl Med. 2017 Sep;58(9):1483-1489
pubmed: 28336779
IEEE Trans Med Imaging. 2015 Oct;34(10):2079-102
pubmed: 25850086
Neuroimage Clin. 2017 Apr 21;15:56-61
pubmed: 28491492
Neurology. 1992 Jan;42(1):183-8
pubmed: 1734300
Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):12075-12080
pubmed: 29078387
Alzheimers Dement (Amst). 2015 Mar 29;1(1):24-32
pubmed: 27239489
Neurology. 2002 Mar 12;58(5):750-7
pubmed: 11889239
J Nucl Med. 2015 Apr;56(4):567-74
pubmed: 25745095
Front Aging Neurosci. 2011 Feb 04;3:2
pubmed: 21331174
Hippocampus. 2016 Feb;26(2):220-8
pubmed: 26286891
PLoS One. 2013;8(3):e58816
pubmed: 23554933
Acta Neuropathol Commun. 2018 Jul 20;6(1):62
pubmed: 30029687
IEEE Trans Med Imaging. 2010 Jun;29(6):1310-20
pubmed: 20378467
Ann Neurol. 2016 Jan;79(1):110-9
pubmed: 26505746
J Neuropathol Exp Neurol. 1998 Jul;57(7):674-83
pubmed: 9690671
Neuroimage Clin. 2019;21:101632
pubmed: 30558867
J Med Imaging (Bellingham). 2014 Jul;1(2):024003
pubmed: 26158035
Arch Neurol. 2009 Dec;66(12):1476-81
pubmed: 20008651
Acta Neuropathol. 2014 Dec;128(6):755-66
pubmed: 25348064
J Alzheimers Dis. 2011;26 Suppl 3:91-5
pubmed: 21971453
Neurology. 2015 Mar 17;84(11):1136-44
pubmed: 25681451
Acta Neuropathol. 2017 May;133(5):705-715
pubmed: 28160067
Neurobiol Aging. 2014 Sep;35(9):2039-45
pubmed: 24684788
J Cogn Neurosci. 2013 Nov;25(11):1851-62
pubmed: 23767922
Neuroimage. 2015 Dec;123:149-64
pubmed: 26275383
Nat Neurosci. 2018 Mar;21(3):424-431
pubmed: 29403032
Int J Epidemiol. 2006 Feb;35(1):49-54
pubmed: 16204333
Hum Brain Mapp. 2010 Sep;31(9):1339-47
pubmed: 20839293
Neurology. 2006 Dec 12;67(11):1942-8
pubmed: 17159098
Arch Neurol. 2012 May;69(5):623-29
pubmed: 22271235
Ann Neurol. 2008 Dec;64(6):698-706
pubmed: 19107993
Neuroimage. 2016 Nov 1;141:542-555
pubmed: 27426838
JAMA. 2015 May 19;313(19):1924-38
pubmed: 25988462
Neurobiol Aging. 2010 Jul;31(7):1077-88
pubmed: 18814937

Auteurs

Thomas D Parker (TD)

The Dementia Research Centre, Queen Square Institute of Neurology, University College London, London, United Kingdom.

David M Cash (DM)

The Dementia Research Centre, Queen Square Institute of Neurology, University College London, London, United Kingdom.

Christopher A S Lane (CAS)

The Dementia Research Centre, Queen Square Institute of Neurology, University College London, London, United Kingdom.

Kirsty Lu (K)

The Dementia Research Centre, Queen Square Institute of Neurology, University College London, London, United Kingdom.

Ian B Malone (IB)

The Dementia Research Centre, Queen Square Institute of Neurology, University College London, London, United Kingdom.

Jennifer M Nicholas (JM)

The Dementia Research Centre, Queen Square Institute of Neurology, University College London, London, United Kingdom.
Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom.

Sarah-Naomi James (SN)

MRC Unit for Lifelong Health and Ageing at University College London, London, United Kingdom.

Ashvini Keshavan (A)

The Dementia Research Centre, Queen Square Institute of Neurology, University College London, London, United Kingdom.

Heidi Murray-Smith (H)

The Dementia Research Centre, Queen Square Institute of Neurology, University College London, London, United Kingdom.

Andrew Wong (A)

MRC Unit for Lifelong Health and Ageing at University College London, London, United Kingdom.

Sarah M Buchanan (SM)

The Dementia Research Centre, Queen Square Institute of Neurology, University College London, London, United Kingdom.

Sarah E Keuss (SE)

The Dementia Research Centre, Queen Square Institute of Neurology, University College London, London, United Kingdom.

Carole H Sudre (CH)

The Dementia Research Centre, Queen Square Institute of Neurology, University College London, London, United Kingdom.
School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom.
Department of Medical Physics and Biomedical Engineering, University College London, London, United Kingdom.

Marc Modat (M)

The Dementia Research Centre, Queen Square Institute of Neurology, University College London, London, United Kingdom.
School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom.
Department of Medical Physics and Biomedical Engineering, University College London, London, United Kingdom.

David L Thomas (DL)

Leonard Wolfson Experimental Neurology Centre, Queen Square Institute of Neurology, University College London, London, United Kingdom.
Neuroradiological Academic Unit, Department of Brain Repair and Rehabilitation, Queen Square Institute of Neurology, University College London, London, United Kingdom.

Sebastian J Crutch (SJ)

The Dementia Research Centre, Queen Square Institute of Neurology, University College London, London, United Kingdom.

Marcus Richards (M)

MRC Unit for Lifelong Health and Ageing at University College London, London, United Kingdom.

Nick C Fox (NC)

The Dementia Research Centre, Queen Square Institute of Neurology, University College London, London, United Kingdom.

Jonathan M Schott (JM)

The Dementia Research Centre, Queen Square Institute of Neurology, University College London, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH